groupH
From EverybodyWiki Bios & Wiki
groupH is an insights and advisory firm working across the pharmaceutical and biotech sectors.
| Private | |
| ISIN | 🆔 |
| Industry | Pharmaceutical Consulting and Market Research |
| Founded 📆 | 2005 |
| Founder 👔 | |
| Headquarters 🏙️ | , , |
Area served 🗺️ | Worldwide |
Key people | Erik Holzinger, Iain Clark, Morris Paterson, Nicolas Touchot, Sara Uttley |
| Members | |
Number of employees | |
| 🌐 Website | grouph |
| 📇 Address | |
| 📞 telephone | |
History[edit]
groupH Ltd was set-up in April 2005, in London, by Erik Holzinger. In 2016, US operations were set up in San Francisco.
Industry Collaborations[edit]
groupH co-ordinates the EphMRA Online Forecasting Forum. This is a forum for pharma companies and agencies to discuss topics of interest in areas of Forecasting and Data Analysis.
- EphMRA forecasting and data analytics round table discussions 2018
- EphMRA forecasting and data analytics round table discussions 2019
Publications[edit]
- Approaches to manage 'affordability' of high budget impact medicines in key EU countries (2018)[1]
- Early Insights from Commercialization of Gene Therapies in Europe (2017)[2]
- Feasibility and attractiveness of indication value-based pricing in key EU countries (2016)[3]
- The payers' perspective on gene therapies (2015)[4]
- Projecting Market Access Success For Early-Stage Pharma Assets: Getting Past The Hurdles (2013)[5]
- Insomnia (2005) [6]
External Links[edit]
Official website https://grouph.com/
References[edit]
- ↑ Flume, Mathias; Bardou, Marc; Capri, Stefano; Sola-Morales, Oriol; Cunningham, David; Levin, Lars-Ake; Postma, Maarten J.; Touchot, Nicolas (2018-01-01). "Approaches to manage 'affordability' of high budget impact medicines in key EU countries". Journal of Market Access & Health Policy. 6 (1): 1478539. doi:10.1080/20016689.2018.1478539. PMC 5998770. PMID 29915664.
- ↑ Touchot, Nicolas; Flume, Mathias (February 2017). "Early Insights from Commercialization of Gene Therapies in Europe". Genes. 8 (2): 78. doi:10.3390/genes8020078. PMC 5333067. PMID 28218692.
- ↑ Flume, Mathias; Bardou, Marc; Capri, Stefano; Sola-Morales, Oriol; Cunningham, David; Levin, Lars-Ake; Touchot, Nicolas; Insight, On behalf of Payers’ (2016-01-01). "Feasibility and attractiveness of indication value-based pricing in key EU countries". Journal of Market Access & Health Policy. 4 (1): 30970. doi:10.3402/jmahp.v4.30970. PMC 4864834. PMID 27226845.
- ↑ Touchot, Nicolas; Flume, Mathias (2015-09-08). "The payers' perspective on gene therapies". Nature Biotechnology. 33 (9): 902–904. doi:10.1038/nbt.3332. ISSN 1546-1696. PMID 26348952.
- ↑ "Projecting Market Access Success For Early-Stage Pharma Assets: Getting Past The Hurdles". In Vivo. 2013-02-19. Retrieved 2019-11-11.
- ↑ Holzinger, E. (May 2005). "Insomnia". IDrugs : The Investigational Drugs Journal. 8 (5): 410–415. ISSN 1369-7056. PMID 15883924.
This article "GroupH" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:GroupH. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
